Sun Life Q2 2026: Broad-Based Growth Pushes ROE to 19.1%, Quieting U.S. Morbidity Fears

What happened

Sun Life Financial reported second‑quarter 2026 underlying net income of C$1.12 billion, up from C$1.02 billion a year earlier, with underlying EPS rising 13% to C$2.02 and underlying ROE reaching 19.1%. The improvement was broad‑based, with earnings increases across Canadian, Asian, and U.S. operations and asset‑management businesses, signaling that the U.S. group benefits turnaround is gaining traction. This performance substantiates management’s repricing strategy and suggests that the elevated morbidity that depressed results through 2025 is receding, while Asia continues its double‑digit growth trajectory. Strong capital levels (LICAT ~154%) and a growing CSM provide a buffer, and the dividend remains well‑covered. With the stock having rallied from the mid‑$50s, a premium valuation of ~16x earnings largely prices in the improved outlook, leaving limited margin for error if execution stumbles.

Implication

Over the investment horizon, sustained 18%+ ROE and mid‑single‑digit EPS growth can drive high‑single‑digit total returns, but investors should demand a margin of safety given the premium valuation; the thesis is intact for those with a multi‑year view.

Thesis delta

The Q2 2026 results materially strengthen the investment thesis. The broad uptick in earnings, especially from the previously troubled U.S. segment, lowers tail risk and elevates conviction in sustained high‑teens ROE. As a result, the base case implied value edges higher, and the stock becomes a clearer buy on dips, though upside from current elevated levels may be more modest.